Your session is about to expire
← Back to Search
Procedure
ALLPS VERSUS PVO Randomized Controlled Trial (ALPPS Trial)
Phase 2
Waitlist Available
Research Sponsored by University of Zurich
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 2012-2015
Awards & highlights
No Placebo-Only Group
Summary
This randomized phase II trial compares how well associating liver partition with portal vein ligation for staged hepatectomy (ALPPS) or portal vein occlusion (PVO) works in treating patients with liver cancer. Both treatments are types of 2-stage hepatectomies for removing liver cancer. ALPPS may be more effective than PVO in patients whose disease would traditionally be considered inoperable. * Trial with surgical intervention
Eligible Conditions
- Liver Tumors
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ 2012-2015
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~2012-2015
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Secondary study objectives
Progression of disease
Awards & Highlights
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.
Trial Design
2Treatment groups
Experimental Treatment
Active Control
Group I: ALPPSExperimental Treatment1 Intervention
Patients undergo Liver partition and portal vein ligation to induce hypertrophy of the future liver remnant
Group II: PVOActive Control1 Intervention
Patient undergo portal vein embolization or ligation
Find a Location
Who is running the clinical trial?
University of ZurichLead Sponsor
1,194 Previous Clinical Trials
1,296,216 Total Patients Enrolled